Clinical utility of liquid biopsy in breast cancer: A systematic review

Primer Autor
Manterola, Carlos
Co-autores
Duque, Galo
Otzen, Tamara
Arias, Cristina
Galindo, Bryan
Mora, Miriann
Guerrero, Enmanuel
Garcia, Nayeli
Título
Clinical utility of liquid biopsy in breast cancer: A systematic review
Editorial
WILEY
Revista
CLINICAL GENETICS
Lenguaje
en
Resumen
Advancements in genetic sequencing techniques along with the identification of specific mutations and structural changes in multiple cancer genes, make it possible to identify circulating tumor cells and cell free nucleic acids as blood-based biomarkers, serving as a liquid biopsy (LB) with great utility for the diagnosis, treatment and follow-up of patients with neoplasms. This systematic review focuses on the clinical utility of LB in patients with breast cancer (BC). Articles published between 1990 and 2021 were included. Databases searched: Trip Database, WoS, EMBASE, PubMed, SCOPUS, and Clinical Keys. Variables studied: Publication year, country, number of cases, primary study design, LB detection methods, genes found, overall survival, disease-free survival, stage, response to treatment, clinical utility, BC molecular type, systemic treatment and methodological quality of primary studies. Of 2619 articles, 74 were retained representing 12 658 patients, mainly cohort studies (66.2%), the majority were from China (15%) and Japan (12.2%). All primary studies described clinical stage and type of systemic treatment used. Most used biomarker detection method: DNA (52.7%) and type of analysis: quantification of total cfDNA (35.1%). PIK3CA mutation was most frequent (62.9%). Evidence suggests clinically useful applications of BC. Though heterogeneous, publications suggest that LB will constitute part of the standard diagnostic-therapeutic process of BC.
Tipo de Recurso
artículo de revisión
doi
10.1111/cge.14077
Formato Recurso
PDF
Palabras Claves
biomarkers
breast cancer
cell free circulating DNA
circulating tumor cells
liquid biopsy
CELL-FREE DNA
CIRCULATING TUMOR-CELLS
POTENTIAL BIOMARKER
INTRATUMOR HETEROGENEITY
METHODOLOGICAL QUALITY
PLASMA
INTEGRITY
MUTATIONS
SERUM
AMPLIFICATION
Ubicación del archivo
http://dx.doi.org/10.1111/cge.14077
Categoría OCDE
Genética y herencia
Materias
biomarcadores
cáncer de mama
ADN celular libre circulante
células tumorales circulantes
biopsia líquida
ADN LIBRE DE CÉLULAS
CÉLULAS TUMORALES CIRCULANTES
BIOMARCADOR POTENCIAL
HETEROGENEIDAD INTRATUMOR
CALIDAD METODOLÓGICA
PLASMA
INTEGRIDAD
MUTACIONES
SUERO
AMPLIFICACIÓN
Título de la cita (Recomendado-único)
Clinical utility of liquid biopsy in breast cancer: A systematic review
Página de inicio (Recomendado-único)
285
Página final (Recomendado-único)
295
Identificador del recurso (Mandatado-único)
artículo de revisión
Versión del recurso (Recomendado-único)
version publicada
Condición de la licencia (Recomendado-repetible)
0
Derechos de acceso
metadata
Access Rights
metadata
Id de Web of Science
WOS:000711160000001
Colecciones
Colección Publicaciones Científicas
Revisa las metricas alternativas de Almetrics
Revisa las citaciones de Dimensions